Acute Myeloid Leukaemia (AML) with Retinoic acid receptor-gamma (RARG) fusions have similarities to Acute Promyelocytic Leukemia (APL) but are not responsive to standard APL treatments.

The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

CCR2 was highly expressed on malignant monocytes from AML patient samples, with cases of acute monocytic leukemia (M5) and acute myelomonocytic leukemia (M4), showing the highest levels of expression.

Asma, 49, was first diagnosed with acute myeloid leukemia in May 2024, a rare and aggressive form of blood cancer. This diagnosis reportedly came just a few years after her successful treatment ...